The FDA has selected influenza vaccine strains for the 2025 to 2026 U.S. flu season, maintaining consistency with prior formulations while incorporating updated epidemiologic and antigenic data to optimize protection.
The FDA's 2025 pulse oximetry guidance introduces stricter accuracy standards, larger study cohorts, and objective skin pigmentation assessment to address measurement bias in darker-skinned patients.
February's FDA approvals feature advancements in cardiology, neurology, infectious diseases, and rare disorders, including the first trials for genetically modified pig kidney transplants and novel treatments for Parkinson’s disease and spinal muscular atrophy.
FDA approves a prefilled syringe format for Purified Cortrophin Gel, reducing administration steps for patients with inflammatory and autoimmune conditions.